Imalumab
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | ? |
Clinical data | |
Other names | BAX69 |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
UNII |
Imalumab (BAX69) is an experimental monoclonal antibody against macrophage inhibitory factor (MIF), a cytokine known to exacerbate tumor growth.[1][2][3] and as of January 2017 it is being tested in Phase IIa clinical trials for metastatic colorectal cancer.[2] It was developed by Cytokine PharmaSciences and Baxalta, which was purchased by Shire Pharmaceuticals.[4]
A phase I/II trial in patients with malignant ascites was terminated in 2016.[4]
References
- ^ Douillard P, Thiele M, Schinagl A, Halama N, Jaeger D, Yazji S, Scheiflinger F, Kerschbaumer R (2015). "Abstract A153: Imalumab, a first-in-class anti-oxidized macrophage migration inhibitory factor (OxMIF) antibody penetrates tumor tissues and shows antitumor activity in patients". Therapeutic Agents: Biological. pp. A153. doi:10.1158/1535-7163.TARG-15-A153.
- ^ a b Clinical trial number NCT02448810 for "Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer" at ClinicalTrials.gov
- ^ Clinical trial number NCT01765790 for "Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumor" at ClinicalTrials.gov
- ^ a b "Imalumab". AdisInsight. Springer Nature Switzerland AG.
Categories:
- Articles with short description
- Short description is different from Wikidata
- Drugs with non-standard legal status
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- Monoclonal antibodies for tumors
- Experimental cancer drugs
- All stub articles
- Monoclonal antibody stubs